[1]刘 杨,张 娟,张静文,等.瓜蒌薤白半夏汤加减治疗非阻塞性冠脉疾病临床研究[J].陕西中医,2023,(7):881-884.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.012]
　LIU Yang,ZHANG Juan,ZHANG Jingwen,et al.Clinical study on Gualou Xiebai Banxia decoction in treatment of non-obstructive coronary artery disease[J].,2023,(7):881-884.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.012]
点击复制

瓜蒌薤白半夏汤加减治疗非阻塞性冠脉疾病临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年7期
页码:
881-884
栏目:
临床研究
出版日期:
2023-07-05

文章信息/Info

Title:
Clinical study on Gualou Xiebai Banxia decoction in treatment of non-obstructive coronary artery disease
作者:
刘 杨; 张 娟; 张静文; 张冰睿
(山东中医药大学附属医院,山东 济南 250014)
Author(s):
LIU Yang; ZHANG Juan; ZHANG Jingwen; ZHANG Bingrui
(Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China)
关键词:
非阻塞性冠脉疾病;  冠脉微循环障碍;  瓜蒌薤白半夏汤;  尼可地尔;  血管内皮功能;  心肺功能
Keywords:
Non-obstructive coronary artery disease;  Coronary microcirculation disturbance;  Gualou Xiebai Banxia decoction;  Nicodil;  Vascular endothelial function;  Cardiopulmonary function
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2023.07.012
文献标志码:
A
摘要:
目的:探讨瓜蒌薤白半夏汤加减治疗非阻塞性冠脉疾病患者冠脉微循环障碍临床疗效。方法:选择非阻塞性冠脉疾病冠脉微循环障碍患者86例,根据随机数字表法分为对照组与观察组,各43例。对照组给予西医常规治疗,观察组在对照组基础上给予瓜蒌薤白半夏汤治疗,观察两组治疗前后临床疗效、中医证候评分、冠脉微循环指标、血管内皮功能、心肺功能指标及安全性评价。结果:治疗后观察组总有效率为93.03%,显著高于对照组的76.74%(P<0.05)。治疗后两组中医证候评分、IMR值、血清TXB2、ET-1水平均较治疗前降低,且观察组低于对照组(P<0.05)。治疗后两组CFR值、VEGF水平、PVO2、AT及PW水平均较治疗前升高,且观察组优于对照组(P<0.05)。结论:瓜蒌薤白半夏汤加减治疗非阻塞性冠脉疾病冠脉微循环障碍患者临床疗效较好。
Abstract:
Objective:To investigate the clinical effect of Gualou Xiebai Banxia decoction in the treatment of coronary microcirculation disorder in patients with non-obstructive coronary artery disease.Methods:86 patients with non-obstructive coronary artery disease of coronary microcirculation disorder were selected and divided into control group and observation group with 43 patients in each group according to random number table method.The control group were treated with western medicine,and the observation group were treated with Gualou Xiebai Banxia decoction on the basis of the control group.To observe the clinical efficacy,TCM syndrome score,coronary microcirculation index of the two groups before and after treatment.To observe the vascular endothelial function,cardiopulmonary function index and safety evaluation of the two groups before and after treatment.Results:After treatment,the observation group total effective rate was 93.03% higher than that in the control group 76.74%(P<0.05).After treatment,the TCM syndrome score,IMR value,serum levels of TXB2 and ET-1 in the two groups were lower than before treatment,the CFR value,VEGF level,PVO2,AT and PW level of the two groups were higher than before treatment,all of these indicators in the observation group were better than the control group(P<0.05).Conclusion:Gualou Xiebai Banxia decoction has better clinical efficacy in the treatment of non-obstructive coronary artery disease patients with coronary microcirculation disorder.

参考文献/References:

[1] Beltrame JF,Tavella R,Jones D,et al.Management of ischaemia with non-obstructive coronary arteries[J].BMJ,2021,37(5):e600-e602.
[2] Zhai C,Fan H,Zhu Y,et al.Coronary functional assessment in non-obstructive coronary artery disease:Present situation and future direction[J].Front Cardiovasc Med,2022,9(1):934-949.
[3] Simion P,Artene B,Achiei I,et al.Myocardial infarction with non-obstructive coronary artery disease:The labyrinth of investigations[J].Case Report and Review of the Literature,2021,11(11):1181.
[4] Dweck MR,Newby DE.Non-obstructive coronary artery disease can no longer be ignored[J].Eur Heart Journal Cardiovasc Imaging,2020,21(5):489-490.
[5] Sechtem U,Brown D,Godo S,et al.Coronary microvascular dysfunction in stable ischaemic heart disease[J].Cardiovasc Res,2020,116(4):771-786.
[6] Pahimi N,Rasool AHG,Sanip Z,et al.An evaluation of the role of oxidative stress in non-obstructive coronary artery disease[J].Journal Cardiovasc Dev Dis,2022,9(2):51.
[7] 袁 彬,何胜虎,邱炜炜,等.伊伐布雷定联合尼可地尔治疗冠状动脉微循环障碍的疗效观察[J].浙江医学,2022,44(21):2330-2333.
[8] 于筱斋.雷诺嗪治疗非阻塞性冠状动脉疾病微循环功能障碍有效性的Meta分析[D].北京:北京协和医学院,2022.
[9] 邵 静,吴 欢.消溶稳斑方对冠脉微循环障碍患者血管内皮功能及炎症因子的影响[J].时珍国医国药,2022,33(4):910-912.
[10] 薛增明,李雅超,杨彦立,等.麝香保心丸联合尼可地尔对心绞痛后冠脉微循环障碍患者的疗效及一氧化氮、血管紧张素Ⅱ、内皮素-1、C-反应蛋白的变化研究[J].辽宁中医杂志,2020,47(6):112-114.
[11] 白玉涵,程 艳,任启珣,等.麝香保心丸联合尼可地尔对冠状动脉微循环障碍患者微循环阻力指数的影响[J].疑难病杂志,2022,21(2):119-123,129.
[12] 黄宝涛,陈 茂.《2020年欧洲非阻塞性冠状动脉缺血疾病专家共识》解读——提高分级诊疗能力,加强全-专联合管理[J].中国全科医学,2021,24(2):125-131.
[13] 中华中医药学会心血管病分会.冠心病稳定型心绞痛中医诊疗指南[J].中医杂志,2019,60(21):1880-1890.
[14] 康利锐,袁晶晶,阿那日,等.芪参益气滴丸对非阻塞性冠状动脉缺血疾病患者冠状动脉微循环功能障碍的影响[J].中南药学,2021,19(5):1014-1018.
[15] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:69.
[16] 冯 娟,闫奎坡,朱明军,等.瓜蒌薤白半夏汤联合血府逐瘀汤从痰瘀论治冠心病心绞痛疗效Meta分析[J].陕西中医,2021,42(3):393-397.
[17] 龚显田,陈丽梅,李子才,等.瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛临床研究[J].陕西中医,2021,42(7):886-889.
[18] 向义桂,张前燕,熊青峰,等.微循环阻力指数与非心肌梗死冠心病病人心肌微循环状态的相关性分析[J].中西医结合心脑血管病杂志,2020,18(5):792-796.
[19] 王晓阳,秦 纲,李变玲,等.尼可地尔治疗原发性微血管心绞痛患者的疗效分析[J].中国循证心血管医学杂志,2022,14(6):704-707.
[20] 和焕香,郭庆梅.瓜蒌化学成分和药理作用研究进展及质量标志物预测分析[J].中草药,2019,50(19):4808-4820.
[21] 王 荣,白思慧,王露露,等.薤白的化学成分和药理作用研究进展[J].中国野生植物资源,2021,40(10):73-82.
[22] 尹培永,熊 婷,吴文虎.逍遥通脉汤联合西药治疗气滞血瘀型冠心病稳定型心绞痛的疗效及对冠脉微循环、血管内皮功能的影响[J].四川中医,2022,40(7):90-93.
[23] 叶伟云,王晓霞,陈小林,等.体外反搏联合尼可地尔治疗冠脉微循环障碍疗效及对血管内皮功能的影响[J].河北医学,2020,26(11):1900-1906.

备注/Memo

备注/Memo:
基金项目:山东省自然科学基金中医药联合基金培育项目(ZR2021LZY011); 山东省自然科学基金中医药联合基金重点支持项目(ZR2021LZY038); 山东省中医药科技发展计划项目(2021M180,2015-088); 山东省中医药特色疗法挖掘整理项目(3700020699)
更新日期/Last Update: 2023-07-10